Myhep Lvir 12 Weeks

Discount 277.00 USD

523.00 USD
- +

Drug profile

Myhep LVIR tablets are comes under anti-viral group

Myhep LVIR tablets which has procure by a patients only with prescription

Myhep LVIR tablets fixed dose combination, contains sofosbuvir and ledipasvir


Trade name: Myhep LVIR

Active components: sofosbuvir & ledipasvir

Strength of the components: 400mg & 90mg respectively

Mfg: Mylan 

Package: 28 tablets in a container

Category: Anti-Viral agent


Myhep LVIR Prescribing Information

Myhep LVIR is a very effective drug, involves in the treatment of chronic hepatitis C viral infection

Myhep LVIR is a single dose medicine, used alone or combination with other anti-viral medicines in chronic condition.

Myhep LVIR, used by the patients having valid prescription


Myhep LVIR Mechanism of Action

Myhep LVIR has two eminent compounds like;

Sofosbuvir & ledipasvir

Myhep LVIR is directly acting anti-viral drug, exhibits its activity by inhibiting the viral replication

Ledipasvir: exhibits its action by intercedes with NS5A activity which is important for viral multiply, secretion and colony of HCV virions. Due to effect of ledipasvir, NS5A inhibitor causes eradicate viral growth

Sofosbuvir: Generally it is anti-hepaciviral associated with NS5B polymerase inhibitor. This polymerase enzyme is responsible for viral proliferation, by interfering with these enzymes causes stoppage of viral reproduction acts as chain terminator



The absorption of Myhep LVIR occurs rapidly, the peak plasma concentration of sofosbuvir 0.8 to 1 hour, ledipasvir is 4 to 4.5 hours; and GS-331007 3.5 to 4 hours



Myhep LVIR should be administered with or without food; the human plasma protein bound of ledipasvir is occurs as >99.8%; sofosbuvir 61 to 65%.

The metabolite of sofosbuvir GS-331007 has minimal plasma protein bounding capability



Myhep LVIR tablet contains ledipasvir which is not metabolized hepatically and is excreted through feces as an unchanged form. Sofosbuvir metabolized to pharmacologically active form GS-461203



Myhep LVIR Excretion occurs through feces and urine


Urine: 80%, feces: 14%, exhaled air: 3.5%


99% in feces & 1% in urine as an unchanged


When to take Myhep LVIR tablets

Myhep LVIR tablets should be taken as a once a day, with or without meal

Myhep LVIR is used either alone or with combination

Myhep LVIR is a prescription medicine; care should be taken to avoid the self medication problems


Dosage Regimens

In pediatric:

Used for HCV infection:

Duration of therapy:

Genotype IV, V or VI:

Therapy naïve and experienced without cirrhosis or with compensated cirrhosis:

Myhep LVIR followed for 12 weeks as a single dose

Genotype I:

Therapy naïve with compensated cirrhosis or without cirrhosis:

Myhep LVIR recommended for 12 weeks as single dose

Therapy experienced without cirrhosis:

Myhep LVIR taken orally as a single dose for 12 weeks

Therapy naïve and experienced without cirrhosis or with compensated cirrhosis:

Myhep LVIR taken for 24 weeks as a single dose

Myhep LVIR is majorly indicated in pediatric patients with the age of 12 or older or weight of 35kg

<12 years or <35kg: the safety and efficacy has not been established

≥12 years or ≥35kg: one tablet to be taken as single dose


In adults:

The recommended dose of Myhep LVIR tablets in adults are;

One tablet 90mg/400mg to be taken as a single dose

Patients acquired without cirrhosis or with compensated cirrhosis:

Myhep LVIR should be taken as single dose orally for 12 weeks

Therapy experienced without cirrhosis:

Myhep LVIR should be taken as once a day for 12 weeks

Therapy experienced with compensated cirrhosis:

Myhep LVIR should be taken as single dose for 24 weeks alone or combination with ribavirin


In decompensated cirrhosis:

Myhep LVIR combined with weight based ribavirin followed for 12 weeks

Ribavirin dosage regimen:

<75kg: 1000mg per day

≥75kg: 1200mg per day

In Genotype I or IV:

Spontaneous therapy and therapy competent without cirrhosis or with compensated cirrhosis:

Myhep LVIR with ribavirin taken for 12 weeks as a single dose

In genotype IV, V or VI:

Therapy experienced and therapy naïve without cirrhosis or with compensated cirrhosis:

Myhep LVIR should be taken as single dose for 12 weeks


Dosage adjustment:

In renal and hepatic impairment patients, mild or moderate conditions, on dosage adjustments required

In decompensated condition, safety and efficacy has not been established

Myhep LVIR Called side effects

Adverse effects in cirrhosis condition;

Asthenia, headache, fatigue, Myalgia, dyspnea, dizziness and irritability

Elevation of bilirubin levels

Elevation of lipase level

Elevation of creatine kinase levels

In cardiac: bradycardia, cardiac arrest

Skin: angioedema and rashes

Serious bradycardia occurs

While combining with ribavirin, related problems occurs

Common side effects;







Drug Interaction

Myhep LVIR concomitant with other drugs likes;

Myhep LVIR With antacids: like proton pump inhibitors, H2 receptor antagonist causes reduce effect of concentration of ledipasvir

Myhep LVIR with HMG CoA reductase: increase the effect of concentration of these lipid mimic drugs

Myhep LVIR With amiodarone: serious bradycardia occurs

Myhep LVIR With digoxin: increase the effect of concentration of digoxin

Myhep LVIR With anti-convulsants: reduce the effect of concentration of Sofosbuvir and ledipasvir

Ledipasvir: Drug transporter P-gp inhibitors and breast cancer resistance protein inhibitor, while concomitant with Sofosbuvir and ledipasvir may causes increase the intestinal absorption of these substrates

Myhep LVIR With anti-mycobacterials: reduce the effect of concentration of Sofosbuvir and ledipasvir


Food -Drug Interactions

Food drug interaction in Myhep LVIR tablets; food does not interfere with the activity of Myhep LVIR

Herbal product like st. Johns wort combined with Myhep LVIR may causes loss of effect of concentration of Myhep LVIR


Possible Contraindications

Myhep LVIR tablets are contraindicated;

Renal and hepatic impairment patients

While combining with ribavirin contraindicated to pregnancy conditions

Hypersensitivity reactions occur


Safety Measures

Exposed to adverse effects due to concomitant with ribavirin

Risk of reaction of HBV infection to HCV/HBV co infected patients

Possibility of symptomatic bradycardia occurs during combination with ribavirin

Risk of loss of therapeutic effect because of combination with P-gp inducers

Care taken in hepatic and renal impairment patients


Pregnancy and Lactation

Myhep LVIR with ribavirin pregnancy category: X

Ribavirin causes fetal death

Myhep LVIR pregnancy category: B1

Myhep LVIR is safe to use in case of monotherapy (used alone)

Breast feeding is not recommended for the patients who are getting ribavirin


Storage and Handling

Myhep LVIR tablets container should be stored at room temperature below 30oC

Myhep LVIR Container should be keep away from moisture, heat and light


Missed dose

If patient fail to take the dose Myhep LVIR, must consult with medical practitioner and administered the missed dose as soon as possible within the time. Myhep LVIR tablets are prescription use, before taking the tablet patient must advice by physician for avoiding self medication

Otherwise the missed dose should be skipped and maintain the regular dosing schedule

Do not take overdose


Over dosage

The maximum dose of Myhep LVIR (Sofosbuvir and ledipasvir) was 1200mg and 120mg twice daily for 10days.

No special antidote is recommended for over dosage of ledipasvir and Sofosbuvir

Hemodialysis is suitable for elimination of ledipasvir hence; ledipasvir is largely bound to plasma protein and also helps to expel the dominant circulating metabolite of Sofosbuvir GS-331007 with range of 53%

If over dosage of both drugs, patients should be examine for confirmation of toxicity


Other precaution: in case of over dosage, contact poison information centre as soon as possible

    No comments yet
Write a comment
Your name
Your name

Sale of day

Choice of buyers. Only popular options!Choice of buyers.
Only popular options!

view all
Dr. Reddy’s
Eisai Pharma
Sun Pharma
  • Children born with HIV
    Children born with HIV
    Children born with HIV accessing treatment, have no significant difference in their movement skills, social interaction, language skills or practical reasoning at age five compared to HIV-negative children, according to new research....